BioSig Technologies Inc. Announces Proposed Public Offering

Core Viewpoint - BioSig Technologies, Inc. has announced its intention to offer shares of common stock through an underwritten public offering, following its recent merger with Streamex Exchange Corporation [1] Group 1: Offering Details - The offering will include shares of common stock or pre-funded warrants, with the completion subject to market conditions [1] - The net proceeds from the offering are intended for purchasing gold bullion, working capital, and general corporate purposes [1] - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, declared effective by the SEC on December 17, 2024 [3] - A preliminary prospectus supplement will be filed with the SEC, and interested parties are encouraged to read the documents for more information [3] Group 3: Company Background - BioSig Technologies is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6] - The PURE EP™ Platform developed by the company allows for real-time acquisition of raw signal data, enhancing procedural success in ablation treatments [7] - Streamex, a wholly owned subsidiary of BioSig, focuses on gold tokenization and building infrastructure for the gold market [5]